Dengue Vaccines Market: Introduction
According to the report, the global dengue vaccines market was valued at US$ 0.4 Bn in 2020 and is projected to expand at a CAGR of 11% from 2021 to 2031. Dengue is a mosquito-borne tropical disease caused by dengue virus. Symptoms usually begin three to 14 days after infection. These include high fever, vomiting, headache, muscle & joint pain, and a characteristic skin rash. A vaccine to prevent dengue (Dengvaxia) has been licensed, and is available in some countries for people aged between nine and 45 years. The World Health Organization recommends that the vaccine should only be given to persons with confirmed prior history of dengue virus infection. The vaccine manufacturer, Sanofi Pasteur, announced in 2017 that people who receive the vaccine and have not previously infected by the virus could be at risk of developing severe dengue, if they are infected after being vaccinated.
Disrupted sanitation services and curtailed water supply lead to conditions that assist mosquito breeding and proliferation, while warm temperatures lead to longer active season for mosquitos. Climate change is likely to increase the burden of dengue, which, in turn, is anticipated to boost the growth of the global dengue vaccines market. The market in Asia Pacific is expected to expand at a high CAGR from 2021 to 2031, owing to highly developed healthcare sector, rise in prevalence of dengue, and continuous evolution of dengue vaccines. The region offers significant opportunities in the dengue vaccines market.
Looking for a complete analysis of competitive dynamics? , Get the PDF Sample Copy of this report: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=28397
Increase in Incidence of Dengue to Drive Dengue Vaccines Market
The number of cases of dengue has increased over the past few years. Major regions of the world affected by dengue are the Americas, Africa, Southeast Asia, the Eastern Mediterranean, and the Western Pacific. Increase in incidence of dengue is likely to fuel the growth of the global dengue vaccines market during the forecast period.
Key Segmentation of Dengue Vaccines Market
In terms of category, the global dengue vaccines market has been divided into live attenuated vaccines, chimeric live attenuated vaccines, and others. The live attenuated vaccines segment accounted for 32.95% share of the global market in 2020. The segment is anticipated to expand at a CAGR of 10% from 2021 to 2031. In terms of product, the global dengue vaccines market has been bifurcated into CYD-TDV (Dengvaxia) and others. The CYD-TDV (Dengvaxia) segment accounted for 97.50% share of the market in 2020. The segment is likely to expand at a CAGR of 10.98% from 2021 to 2031.
Based on route of administration, the global dengue vaccines market has been classified into subcutaneous and others. The subcutaneous segment accounted for 75.62% share of the market in 2020. The segment is projected to expand at a CAGR of 11% from 2021 to 2031. Dengvaxia is given by the doctor or nurse as an injection underneath the skin (subcutaneous route) in the upper arm. Adults or children will receive three injections of 0.5 mL each at 6-month intervals. Currently, Dengvaxia is the only approved drug for dengue, which is used in dengue treatment.
In terms of end user, the global dengue vaccines market has been divided into hospitals, government institutes, specialty clinics, and others. The hospitals segment dominated the global market in 2020. The segment is anticipated to reach US$ 1.08 Bn by 2031.
Are you a start-up willing to make it big in the business? Grab an exclusive PDF Brochure of this report: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=28397
Asia Pacific to Lead Dengue Vaccines Market
In terms of region, the global dengue vaccines market has been divided into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Asia Pacific dominated the global dengue vaccines market in 2020, followed by Latin America. Asia Pacific’s significant market share can be ascribed to presence of a large number of key players, rise in prevalence of dengue, improving healthcare infrastructure, and funding from governments and large corporates. Brazil and Mexico are the leading markets in the region, due to the rise in investment in development of well-equipped health care institutions and rise in prevalence of dengue cases.
Competition Landscape of Dengue Vaccines Market
The global dengue vaccines market is fragmented in terms of number of players. Key players operating in the global market include Sanofi Pasteur Limited, Takeda Pharmaceutical Company Limited, Merck Co. & Inc., GlaxoSmithKline plc, GeneOne Life Science, Medigen Vaccine Biologics, Panacea Biotec Limited, Sun Pharmaceutical Industries Ltd., Serum Institute of India Pvt. Ltd., Biological E, and VabioTech.
Global Dengue Vaccines Market: Segmentation
- Dengue Vaccines Market, by Category
- Live Attenuated Vaccines
- Chimeric Live Attenuated Vaccines
- Others
- Dengue Vaccines Market, by Product
- CYD-TDV (Dengvaxia)
- Others
- Dengue Vaccines Market, by Route of Administration
- Subcutaneous
- Others
- Dengue Vaccines Market, by End User
- Hospitals
- Government Institutes
- Specialty Clinics
- Others
About Us
Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of analysts, researchers, and consultants, uses proprietary data sources and various tools and techniques to gather and analyze information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
Contact
Transparency Market Research,
90 State Street, Suite 700,
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: [email protected]
